Showing results (111-120 of 252) with videos related to
Sort By:
Pageof 26
Annals of Hematology|November 29, 2023
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbiditiesNathan P Horvat, Enas F Abdallah, Zhuoer Xie, et al.American Journal of Hematology|March 25, 2023
Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemiaAshley Rose, Ling Zhang, Akriti G Jain, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution ExperienceJulio C Chavez, Samir Dalia, Jose Sandoval-Sus, et al.Annals of Hematology|November 24, 2017
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromesVu H Duong, Eric Padron, Najla H Al Ali, et al.Leukemia Research|February 20, 2016
Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemiaYaman Suleiman, Samir Dalia, Jane Jijun Liu, et al.Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.Biorxiv : the Preprint Server for Biology|January 30, 2023
HuR inhibition reduces post-ischemic cardiac remodeling by dampening acute inflammatory gene expression and the innate immune responseSamuel Slone, Sarah R Anthony, Lisa C Green, et al.Journal of Molecular and Cellular Cardiology|November 13, 2022
HuR-dependent expression of Wisp1 is necessary for TGFβ-induced cardiac myofibroblast activityLisa C Green, Samuel Slone, Sarah R Anthony, et al.The Oncologist|February 10, 2017
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee ExperienceTodd C Knepper, Gillian C Bell, J Kevin Hicks, et al.Annals of Hematology|December 1, 2017
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuationAndrew T Kuykendall, Savan Shah, Chetasi Talati, et al.Pageof 26